FUJIFILM Diosynth Biotechnologies Newsletter – April 2024

Expansion of Our Manufacturing Agreement with argenx for the Treatment of Severe Autoimmune Diseases?

We were pleased to share the news that we are expanding our manufacturing agreement with argenx to provide drug product and finished goods services for efgartigimod, a monoclonal antibody (mAb) fragment to target the neonatal Fc receptor (FcRn), in patients with severe autoimmune disease. This is part of our commitment to manufacture vital medicines and to fulfill our role as true Partners for Life.? ?

$1.2 Billion Investment to Expand Our Large-Scale Cell Culture CDMO Business in North Carolina?

FUJIFILM Corporation announced an investment of $1.2 billion to further expand the FUJIFILM Diosynth Biotechnologies end-to-end bio-manufacturing facility in Holly Springs, North Carolina – which will include an additional 680 highly-skilled local jobs by 2031.???

Transforming the Biopharmaceutical Industry: Addressing Patient Access to Medicines with Interconnected Networks?

Within the contract development and manufacturing organization (CDMO) space of biopharmaceuticals, CDMOs have focused on ways to overcome challenges customers face to meet their needs more effectively. Learn more about how we are moving beyond the traditional CDMO transactional business model with our Partners for Life strategy to provide a holistic approach to customers’ entire pipelines, and how our KojoX? operating philosophy aims to transform the biopharmaceutical industry.?

?

The Perfect Hosts for Vaccine and Virus Expression: Insect Cell Expression Systems?

For over 20 years, we have developed and commercialized multiple insect cell culture projects at various stages of readiness. Our knowledge helps customers to define a strategy to develop, scale-up and manufacture baculovirus expression vector systems (BEVS). Learn more about our solutions that ensure?insect cell programs are successful from process development through to commercialization.?

?

De-risking the Development of Tomorrow’s Medicines with Advancing Analytical Characterization Capabilities?

In this webinar, Jason Barker, PhD., Director of Analytical & Formulation Development at FUJIFILM Diosynth Biotechnologies explores the advancements in mass spectrometry, biophysical characterization, automated sample preparation, and high-throughput analytics that are crucial for achieving these goals.?

?

Expanding the characterization landscape for biopharmaceuticals using mass spectrometry?

April 25, Cambridge, MA (in-person)?

This Lunch & Learn will provide insight into our mass spectrometry techniques and services we offer for your biopharmaceuticals’ characterization. We will discuss how mass spectrometry is being incorporated to leverage routine capabilities, and take an in-depth look at innovative applications for extended characterization. Book your spot here.?

?

ASGCT?

May 7-11, Baltimore, MD?

Schedule a meeting with our team via the event app or stop by booth 1927 to learn more about FUJIFILM Diosynth Biotechnologies’ capabilities.?

?

BIO Korea??

May 8-10, Seoul??

We are delighted to exhibit with FUJIFILM Toyama Chemical at BIO Korea. Schedule a meeting with our team via BIO One to One Partnering or stop by booth J19 to connect with us.?